- 作者：Sara Massironi<sup>asup><sup> ; sup><sup>sara.massironi@policlinico.mi.it" class="auth_mail" title="E-mail the corresponding authorsup> ; Alessandra Zilli<sup>asup><sup> ; sup><sup>bsup> ; Ilaria Fanetti<sup>asup><sup> ; sup><sup>bsup> ; Clorinda Ciafardini<sup>asup><sup> ; sup><sup>bsup> ; Dario Conte<sup>asup><sup> ; sup><sup>bsup> ; Maddalena Peracchi<sup>asup><sup> ; sup><sup>bsup>
- 关键词：Lanreotide ; Neuroendocrine tumours ; Octreotide
- 刊名：Digestive and Liver Disease
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：47
- 期：11
- 页码：978-983
- 全文大小：610 K
sSec_2">Aims
spar0010">This prospective study evaluates the outcome of patients with recurrent type-1 gastric carcinoids treated with somatostatin analogues.
sSec_3">Methods
spar0015">From 2000 to 2013, among a population of 107 chronic atrophic gastritis patients, 25 (20% males, median age 62 years) developed type-1 gastric carcinoids and underwent regular clinical and endoscopic follow-up (median 77 months, range 6–165) after the initial treatment. Those patients showing recurrent disease were treated with somatostatin analogues until carcinoid disappearance.
sSec_4">Results
spar0020">12/25 patients (33% males, median age 65 years) showed recurrent gastric carcinoids and were treated with somatostatin analogues for a median duration of 12 months. Median gastrin and chromogranin A levels, which were 802 pg/mL and 33 U/L, respectively, decreased to 299 pg/mL (p = 0.002) and 15.6 U/L (p = 0.001) at the end of the treatment. Gastric carcinoids disappeared after a median length of treatment of 12 months. After a median time of 19.5 months from somatostatin analogues discontinuation, 4/12 patients (25% males, median age 56 years) showed a further recurrence. A new cycle of treatment was performed successfully.
sSec_5">Conclusions
spar0025">This study confirms that type-1 gastric carcinoids are a recurring disease and somatostatin analogues, administered on 12-month cycles, represent an effective treatment.